Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma.

As noted by Herms et al., a high discontinuation rate should not be perceived as negative per se as reasons such as satisfactory efficacy or treatment holidays may be significant and cannot be overlooked [ 25 ].

also in 13,097 other papers